Collaboration Aims to Improve Post-Surgical Radiation Therapy
Radformation Inc and Videra Surgical are integrating Videra Surgical’s VeraForm tumor bed marker and Radformation’s AI-driven AutoContour Software to aid in identifying the residual tumor bed for post-surgical radiation therapy.
Due to conventional imaging and variability often present with surgical clips, identifying and contouring the tumor bed can sometimes be imprecise during treatment planning. The VeraForm radiopaque, continuous, three-dimensional multi-planar tissue marker can be identified on conventional planning CT images to delineate the tumor bed precisely. When used in conjunction with AutoContour, users are provided with a variety of contouring tools and automated workflows to quickly detect and contour VeraForm. AutoContour generates AI-driven contours for organs at risk, nodal regions in the head, thorax, and pelvis, and automates multiple boolean operations to generate planning volumes to deliver the exact targeting necessary for accurate and effective radiation therapy.
"Videra is committed to forming best-in-class collaborations to further our Women's Health Initiative’s to optimize the standard of care for patients and accelerate the workflow for often time-consuming steps that may impede patient treatment," said Joe Guido, Chief Executive Officer of Videra Surgical. "AutoContour allows VeraForm users to create consistent high-quality contours, and we look forward to applying that standardization to advance the clinical applications of VeraForm.”
“Our collaboration with Videra represents an exciting advancement in localization, visualization and contouring of the treatment bed that could help patients and their physicians achieve positive radiation therapy outcomes. “ said Joe Ianni, Chief Revenue Officer at Radformation. “We anticipate applying Radformation’s automated workflow to additional disease sites as the use of the Videra marker expands.”
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval